Cellular pharmacology of D-3-azido-3-deoxy-myo-inositol, an inhibitor of phosphatidylinositol signaling having antiproliferative activity.

Abstract:

:D-3-Azido-3-deoxy-myo-inositol (3AMI) is an inhibitor of the growth of v-sis-transformed NIH 3T3 cells but not of wild-type NIH 3T3 cells, whose effects may be mediated through the phosphatidylinositol-3'-kinase pathway. We studied some properties of the cellular pharmacology of 3AMI using high-specific-activity [3H]-3AMI. The uptake of [3H]-3AMI by wild-type NIH 3T3 and v-sis NIH 3T3 cells was similar. [3H]-3AMI was a substrate for phosphatidylinositol synthetase, with the maximal velocity (Vmax) being 1.0 nmol min-1 mg-1 and the Michaelis constant (Km) being 23 mM. Corresponding values obtained for [3H]-myo-inositol as a substrate were 5.5 nmol min-1 mg-1 and 3.2 mM. [3H]-3AMI was incorporated into the cellular inositol lipids of v-sis NIH 3T3 cells to a similar extent as that observed for [3H]-myo-inositol but was not incorporated into the inositol lipids of wild-type NIH 3T3 cells. The [3H]-3AMI incorporated by the v-sis NIH 3T3 cells was present in the phosphatidylinositol and phosphatidylinositol phosphate fractions but not in bisphosphorylated phosphatidylinositol. myo-Inositol antagonized the growth-inhibitory effects of 3AMI. The v-sis NIH 3T3 cells were found to be more sensitive than the wild-type NIH 3T3 cells to growth inhibition (without 3AMI) caused by the removal of myo-inositol from the medium. The results of the study suggest that 3AMI is an antimetabolite of myo-inositol. The relative sensitivity of v-sis NIH 3T3 and some other cells to 3AMI may be a reflection of increased myo-inositol requirements for the growth of these cells as compared with wild-type NIH 3T3 cells.

authors

Brunn G,Fauq AH,Chow S,Kozikowski AP,Gallegos A,Powis G

doi

10.1007/BF00686287

subject

Has Abstract

pub_date

1994-01-01 00:00:00

pages

71-9

issue

1

eissn

0344-5704

issn

1432-0843

journal_volume

35

pub_type

杂志文章
  • Increased cellular accumulation and distribution of amrubicin contribute to its activity in anthracycline-resistant cancer cells.

    abstract:PURPOSE:Multi-drug resistance and cumulative cardiotoxicity are major limitations for the clinical use of anthracyclines. Here, we evaluated and compared the cross-resistance of amrubicin, a third-generation synthetic anthracycline and potent topoisomerase (topo)-II inhibitor with little or no observed cardiotoxicity t...

    journal_title:Cancer chemotherapy and pharmacology

    pub_type: 杂志文章

    doi:10.1007/s00280-011-1782-x

    authors: Mamidipudi V,Shi T,Brady H,Surapaneni S,Chopra R,Aukerman SL,Heise C,Sung V

    更新日期:2012-04-01 00:00:00

  • Analysis of gastric cancer with cDNA microarray.

    abstract::Recent advances in cDNA microarray techniques have enabled us to study the expression of many genes simultaneously. As gastric cancer remains one of the most common cancers in Japan, we studied gene expression profiles in gastric cancer by cDNA microarray analysis to determine if it would be clinically useful. We demo...

    journal_title:Cancer chemotherapy and pharmacology

    pub_type: 杂志文章

    doi:10.1007/s00280-004-0882-2

    authors: Haraguchi N,Inoue H,Mimori K,Tanaka F,Utsunomiya T,Yoshikawa K,Mori M

    更新日期:2004-09-01 00:00:00

  • Absence of cross-resistance between two alkylating agents: BCNU vs bifunctional galactitol.

    abstract::Dianhydrogalactitol (DAG) increased the life span of both BCNU-sensitive and -resistant L1210 tumor-bearing mice. However, the BCNU-resistant strain showed slightly lower sensitivity against DAG, which could be overcome by an increase in drug dose of ca. 20%. The somewhat lower sensitivity was proportional to a slight...

    journal_title:Cancer chemotherapy and pharmacology

    pub_type: 杂志文章

    doi:10.1007/BF00304764

    authors: Institóris E,Szikla K,Otvös L,Gál F

    更新日期:1989-01-01 00:00:00

  • Inhibition of intracellular Ca2+ signalling, cytotoxicity and antitumor activity of the herbicide oryzalin and its analogues.

    abstract:PURPOSE:Studies were conducted on oryzalin (3,5-dinitro-N,N-di(n-propyl)sulfanilamide), a widely used dinitroaniline sulfonamide herbicide, which was identified from plant extracts as an inhibitor of mitogen- and growth factor-mediated intracellular free Ca2+ ([Ca2+]i) signalling in mammalian cells. METHODS AND RESULT...

    journal_title:Cancer chemotherapy and pharmacology

    pub_type: 杂志文章

    doi:10.1007/s002800050703

    authors: Powis G,Gallegos A,Abraham RT,Ashendel CL,Zalkow LH,Dorr R,Dvorakova K,Salmon S,Harrison S,Worzalla J

    更新日期:1997-01-01 00:00:00

  • Effect of NQO1 induction on the antitumor activity of RH1 in human tumors in vitro and in vivo.

    abstract::NQO1 is a reductive enzyme that is important for the activation of many bioreductive agents and is a target for an enzyme-directed approach to cancer therapy. It can be selectively induced in many tumor types by a number of compounds including dimethyl fumarate and sulforaphane. Mitomycin C is a bioreductive agent tha...

    journal_title:Cancer chemotherapy and pharmacology

    pub_type: 杂志文章

    doi:10.1007/s00280-004-0961-4

    authors: Digby T,Leith MK,Thliveris JA,Begleiter A

    更新日期:2005-09-01 00:00:00

  • Effect of hemoglobin solution on the response of intracranial and subcutaneous 9L tumors to antitumor alkylating agents.

    abstract::The 9L gliosarcoma growing subcutaneously in the hind leg of the Fisher 344 rat contains major areas of severe (< 5 mmHg) hypoxia, making up about 49% of the tumor. Intravenous administration of an ultrapurified polymerized bovine hemoglobin solution (8 ml/kg) along with normal air breathing reduces the percentage of ...

    journal_title:Cancer chemotherapy and pharmacology

    pub_type: 杂志文章

    doi:10.1007/BF00686024

    authors: Teicher BA,Holden SA,Menon K,Hopkins RE,Gawryl MS

    更新日期:1993-01-01 00:00:00

  • Effects of DFMO-induced polyamine depletion on human tumor cell sensitivity to antineoplastic DNA-crosslinking drugs.

    abstract::We investigated the effect of pretreatment with difluoromethylornithine (DFMO), an ornithine decarboxylase inhibitor, on the cytocidal responses of four human adenocarcinoma cell lines to two alkylating and crosslinking agents: chlorambucil and N,N',N"-triethylenethiophosphoramide (thiotepa). The cell lines studied in...

    journal_title:Cancer chemotherapy and pharmacology

    pub_type: 杂志文章

    doi:10.1007/BF00299860

    authors: Seidenfeld J,Komar KA,Naujokas MF,Block AL

    更新日期:1986-01-01 00:00:00

  • A phase II trial of modified FOLFOX6 as first-line therapy for adenocarcinoma of an unknown primary site.

    abstract:PURPOSE:The aim of the study was to assess the clinical activity and toxicity of oxaliplatin and leucovorin in combination with bolus and continuous infusional 5-fluorouracil administered every 2 weeks (modified FOLFOX-6 regimen) to patients with adenocarcinoma of an unknown primary site (ACUP). METHODS:Previously unt...

    journal_title:Cancer chemotherapy and pharmacology

    pub_type: 杂志文章

    doi:10.1007/s00280-015-2904-7

    authors: Shin DY,Choi YH,Lee HR,Na II,Yuh YJ,Kim BS,Chung IJ,Bae WK,Shim HJ,Song EK,Yang SH,Kang HJ

    更新日期:2016-01-01 00:00:00

  • Triclosan inhibits enoyl-reductase of type I fatty acid synthase in vitro and is cytotoxic to MCF-7 and SKBr-3 breast cancer cells.

    abstract:BACKGROUND AND PURPOSE:Human type I fatty acid synthase has been proposed as a chemotherapeutic target for the treatment of breast cancer based on the inactivation of human beta-ketoacyl synthase activity by cerulenin. Triclosan, a common antibiotic, functions by inhibiting the enoyl-reductase enzymes of type II fatty ...

    journal_title:Cancer chemotherapy and pharmacology

    pub_type: 杂志文章

    doi:10.1007/s00280-001-0399-x

    authors: Liu B,Wang Y,Fillgrove KL,Anderson VE

    更新日期:2002-03-01 00:00:00

  • Ibrutinib does not prolong the corrected QT interval in healthy subjects: results from a thorough QT study.

    abstract:PURPOSE:Ibrutinib is an orally administered, irreversible Bruton's tyrosine kinase inhibitor for treatment of B-cell malignancy. This study evaluated the effects of single-dose ibrutinib at therapeutic and supratherapeutic exposures on cardiac repolarization in healthy subjects. METHODS:Part 1 used an open-label, two-...

    journal_title:Cancer chemotherapy and pharmacology

    pub_type: 杂志文章

    doi:10.1007/s00280-017-3471-x

    authors: de Jong J,Hellemans P,Jiao JJ,Huang Y,Mesens S,Sukbuntherng J,Ouellet D

    更新日期:2017-12-01 00:00:00

  • Brain uptake and anticancer activities of vincristine and vinblastine are restricted by their low cerebrovascular permeability and binding to plasma constituents in rat.

    abstract::Unidirectional blood-brain barrier transfer of the lipophilic anticancer agents vincristine and vinblastine was studied in anesthetized rats, using an isolated, in situ brain perfusion technique. Drug binding to plasma constituents was also measured. Despite the high lipophilicity of these agents (the log octanol/phys...

    journal_title:Cancer chemotherapy and pharmacology

    pub_type: 杂志文章

    doi:10.1007/BF02897227

    authors: Greig NH,Soncrant TT,Shetty HU,Momma S,Smith QR,Rapoport SI

    更新日期:1990-01-01 00:00:00

  • Toxicity and metabolism of 3'-deoxyadenosine N1-oxide in mice and Ehrlich ascites tumor cells.

    abstract::The toxic effect of 3'-deoxyadenosine N1-oxide (3'-dANO) on mice, on their different organs, and on Ehrlich ascites tumor cells was studied. In both healthy and tumour-bearing animals, the lethal dose for 10% of the mice receiving i.p. injections (LD10) of 3'-dANO was estimated to be about 300 mg/kg x 4 days in one mo...

    journal_title:Cancer chemotherapy and pharmacology

    pub_type: 杂志文章

    doi:10.1007/BF00686398

    authors: Svendsen KR,Overgaard-Hansen K,Frederiksen S,Engelholm SA,Pedersen NT,Vindeløv LL

    更新日期:1992-01-01 00:00:00

  • Plasma pharmacokinetics and oral bioavailability of 3,4,5,6-tetrahydrouridine, a cytidine deaminase inhibitor, in mice.

    abstract::Cytidine analogues such as cytosine arabinoside, gemcitabine, decitabine, 5-azacytidine, 5-fluoro-2'-deoxycytidine and 5-chloro-2'-deoxycytidine undergo rapid catabolism by cytidine deaminase (CD). 3,4,5,6-tetrahydrouridine (THU) is a potent CD inhibitor that has been applied preclinically and clinically as a modulato...

    journal_title:Cancer chemotherapy and pharmacology

    pub_type: 杂志文章

    doi:10.1007/s00280-007-0625-2

    authors: Beumer JH,Eiseman JL,Parise RA,Florian JA Jr,Joseph E,D'Argenio DZ,Parker RS,Kay B,Covey JM,Egorin MJ

    更新日期:2008-08-01 00:00:00

  • Interleukin-1 receptor antagonist attenuates cyclophosphamide-induced mucositis in a murine model.

    abstract:PURPOSE:Cyclophosphamide is a cytotoxic chemotherapy drug that causes severe damages to hematopoietic and gastrointestinal systems. The aim of this study is to evaluate the protective effects of recombinant human interleukin-1 receptor antagonist (rhIL-1Ra) on chemotherapy-induced mucositis (CIM) in a murine model of c...

    journal_title:Cancer chemotherapy and pharmacology

    pub_type: 杂志文章

    doi:10.1007/s00280-010-1439-1

    authors: Xiang D,Guo Y,Zhang J,Gao J,Lu H,Zhu S,Wu M,Yu Y,Han W

    更新日期:2011-06-01 00:00:00

  • Recombinant anti-carcinoembryonic antigen antibodies for targeting cancer.

    abstract::Antibodies can be used to target cancer therapies to malignant tissue; the approach is attractive because conventional treatments such as chemo- and radiotherapy are dose limited due to toxicity in normal tissues. Effective targeting relies on appropriate pharmacokinetics of antibody-based therapeutics, ideally showin...

    journal_title:Cancer chemotherapy and pharmacology

    pub_type: 杂志文章,评审

    doi:10.1007/pl00014055

    authors: Chester KA,Mayer A,Bhatia J,Robson L,Spencer DI,Cooke SP,Flynn AA,Sharma SK,Boxer G,Pedley RB,Begent RH

    更新日期:2000-01-01 00:00:00

  • Evaluating primary intra-arterial chemotherapy versus intravenous plus intra-arterial chemotherapy for advanced intraocular retinoblastoma.

    abstract:PURPOSE:Although intra-arterial chemotherapy (IAC) is commonly used for treating intraocular retinoblastoma, it is not a systemic therapy. We aimed to investigate whether the addition of intravenous chemotherapy (IVC) before IAC administration had any effects (whether beneficial or adverse) on patient outcomes. METHOD...

    journal_title:Cancer chemotherapy and pharmacology

    pub_type: 杂志文章,多中心研究

    doi:10.1007/s00280-020-04036-w

    authors: Chen Q,Zhang B,Dong Y,Mo X,Zhang L,Xia J,Zhang J,Zhang S

    更新日期:2020-04-01 00:00:00

  • Phase II study of erlotinib in elderly patients with non-small cell lung cancer harboring epidermal growth factor receptor mutations.

    abstract:PURPOSE:Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors are key drugs in the treatment of non-small cell lung cancer (NSCLC) harboring EGFR activating mutations. We assessed the efficacy and safety of one EGFR tyrosine kinase inhibitor, erlotinib, in elderly Japanese patients with EGFR-mutated NSCLC....

    journal_title:Cancer chemotherapy and pharmacology

    pub_type: 杂志文章,多中心研究

    doi:10.1007/s00280-015-2784-x

    authors: Inoue Y,Inui N,Asada K,Karayama M,Matsuda H,Yokomura K,Koshimizu N,Imokawa S,Yamada T,Shirai T,Kasamatsu N,Suda T

    更新日期:2015-07-01 00:00:00

  • Phase II trial of vindesine and VP16-213 in the palliation of poor-prognosis patients and elderly patients with small cell lung cancer.

    abstract::Forty-three previously untreated patients, all of whom had poor-prognosis small cell lung cancer and/or were greater than 65 years old, received treatment with vindesine and VP16-213. Thirteen patients had limited disease and 30 extensive disease. Response rates (CR + PR) of 86% (CR 29%) and 66% (CR 17%) were seen in ...

    journal_title:Cancer chemotherapy and pharmacology

    pub_type: 杂志文章

    doi:10.1007/BF00257124

    authors: Allan SG,Gregor A,Cornbleet MA,Leonard RC,Smyth JF,Grant IW,Crompton GK

    更新日期:1984-01-01 00:00:00

  • Angiostatin potentiates cyclophosphamide treatment of metastatic disease.

    abstract:PURPOSE:We examined the interaction between cyclophosphamide (CPA) and angiostatin (AS) on the growth of primary Lewis lung carcinoma (LLC) tumors and on the development of LLC pulmonary metastases. We studied the effects of AS and CPA on the stages of angiogenesis employing in vitro assays. METHODS:Primary tumor grow...

    journal_title:Cancer chemotherapy and pharmacology

    pub_type: 杂志文章

    doi:10.1007/s00280-002-0514-7

    authors: Mauceri HJ,Seetharam S,Beckett MA,Schumm LP,Koons A,Gupta VK,Park JO,Manan A,Lee JY,Montag AG,Kufe DW,Weichselbaum RR

    更新日期:2002-11-01 00:00:00

  • D-dimer increase: an unfavorable factor for patients with primary liver cancer treated with TACE.

    abstract:PURPOSE:To explore the clinical significance of plasma D-dimer increase for transcatheter arterial chemoembolization (TACE) in patients with primary liver cancer (PLC). METHODS:The clinical data of 80 PLC patients who underwent TACE in our hospital from January 2015 to January 2017 were collected, including the plasma...

    journal_title:Cancer chemotherapy and pharmacology

    pub_type: 杂志文章

    doi:10.1007/s00280-019-03778-6

    authors: Chen X,Chang Z,Liu Z

    更新日期:2019-04-01 00:00:00

  • Taxol cytotoxicity on human leukemia cell lines is a function of their susceptibility to programmed cell death.

    abstract::Taxol is the prototype of a class of antineoplastic drugs that target microtubules. It enhances tubulin-monomer polymerization and stabilizes tubulin polymers, increasing the fraction of cells in the G2 or M phase of the cell cycle. We report that treatment of HL-60 and U937 myeloid cell lines with 1-10 microM taxol i...

    journal_title:Cancer chemotherapy and pharmacology

    pub_type: 杂志文章

    doi:10.1007/BF00686187

    authors: Gangemi RM,Tiso M,Marchetti C,Severi AB,Fabbi M

    更新日期:1995-01-01 00:00:00

  • Synthesis of short retinoidal amides related to fenretinide: antioxidant activities and differentiation-inducing ability.

    abstract:PURPOSE:By a scaffold shortening strategy, a small series of retinoidal amides fenretinide (4-HPR) analogs have been synthesized from α, β-ionones and tested for their antiproliferative and differentiating activities, and antioxidant effect. METHODS:The antiproliferative activity and triggering of apoptosis of our sho...

    journal_title:Cancer chemotherapy and pharmacology

    pub_type: 杂志文章

    doi:10.1007/s00280-017-3265-1

    authors: Anzaldi M,Viale M,Macciò C,Castagnola P,Oliveri V,Rosano C,Balbi A

    更新日期:2017-04-01 00:00:00

  • Comparison of systemic availability of curcumin with that of curcumin formulated with phosphatidylcholine.

    abstract:PURPOSE:Curcumin, a major constituent of the spice turmeric, suppresses expression of the enzyme cyclooxygenase 2 (Cox-2) and has cancer chemopreventive properties in rodents. It possesses poor systemic availability. We explored whether formulation with phosphatidylcholine increases the oral bioavailability or affects ...

    journal_title:Cancer chemotherapy and pharmacology

    pub_type: 杂志文章

    doi:10.1007/s00280-006-0355-x

    authors: Marczylo TH,Verschoyle RD,Cooke DN,Morazzoni P,Steward WP,Gescher AJ

    更新日期:2007-07-01 00:00:00

  • Randomized double-blinded, placebo-controlled phase II trial of simvastatin and gemcitabine in advanced pancreatic cancer patients.

    abstract:BACKGROUND:Statins have potential antineoplastic properties via arrest of cell-cycle progression and induction of apoptosis. A previous study demonstrated in vitro and in vivo antineoplastic synergism between statins and gemcitabine. The present randomized, double-blinded, phase II trial compared the efficacy and safet...

    journal_title:Cancer chemotherapy and pharmacology

    pub_type: 杂志文章,多中心研究,随机对照试验

    doi:10.1007/s00280-013-2328-1

    authors: Hong JY,Nam EM,Lee J,Park JO,Lee SC,Song SY,Choi SH,Heo JS,Park SH,Lim HY,Kang WK,Park YS

    更新日期:2014-01-01 00:00:00

  • Preclinical pharmacologic evaluation of geldanamycin as an antitumor agent.

    abstract::The plasma pharmacokinetics of the anti-tumor antibiotic geldanamycin (GM: NSC 122750), a naturally occurring benzoquinoid ansamycin, was characterized in mice and a beagle dog. Concentrations of GM well above 0.1 microgram/ml, which was typically effective against neoplastic cell lines responsive to the drug in vitro...

    journal_title:Cancer chemotherapy and pharmacology

    pub_type: 杂志文章

    doi:10.1007/BF00689048

    authors: Supko JG,Hickman RL,Grever MR,Malspeis L

    更新日期:1995-01-01 00:00:00

  • Intensive chemotherapy for adult lymphoblastic lymphomas.

    abstract::A total of 20 adults patients presenting with previously untreated lymphoblastic lymphoma underwent an intensive chemotherapy protocol. Either the BACOP or the m-BACOD regimen was used for induction. If the patients achieved a complete clinical remission (CR) after three courses, they were given intensive consolidatio...

    journal_title:Cancer chemotherapy and pharmacology

    pub_type: 杂志文章

    doi:10.1007/BF00686341

    authors: Liang R,Todd D,Chan TK,Chiu E,Lie A,Ho FC,Loke SL

    更新日期:1991-01-01 00:00:00

  • Phase I/IIa study of sequential chemotherapy regimen of bendamustine/irinotecan followed by etoposide/carboplatin in untreated patients with extensive disease small cell lung cancer (EDSCLC).

    abstract:PURPOSE:The sequence bendamustine (B) + Irinotecan (I) followed by etoposide (E) + carboplatin (C) was hypothesized to increase progression-free survival (PFS) and overall survival (OS) in untreated extensive-disease small cell lung cancer (EDSCLC) patients compared to historical controls by exploiting mitotic catastro...

    journal_title:Cancer chemotherapy and pharmacology

    pub_type: 杂志文章

    doi:10.1007/s00280-015-2869-6

    authors: Allendorf DJ,Bordoni RE,Grant SC,Saleh MN,Reddy VB,Jerome ML,Dixon PM,Miley DK,Singh KP,Robert F

    更新日期:2015-11-01 00:00:00

  • Looking for answers: the current status of neoadjuvant treatment in localized soft tissue sarcomas.

    abstract:PURPOSE:Sarcomas are a rare and heterogeneous variant of cancer. The standard of care treatment involves surgical resection with radiation in high-risk patients. Despite appropriate treatment approximately 50 % of patients will suffer and die from recurrent disease. The purpose of this article is to review the current ...

    journal_title:Cancer chemotherapy and pharmacology

    pub_type: 杂志文章,meta分析,评审

    doi:10.1007/s00280-016-3055-1

    authors: Nathenson MJ,Sausville E

    更新日期:2016-11-01 00:00:00

  • Preoperative radiotherapy with capecitabine and mitomycin C in locally advanced rectal carcinoma.

    abstract:PURPOSE:To evaluate the efficacy and safety of preoperative radiotherapy with capecitabine and mitomycin C in patients with locally advanced rectal cancer. METHODS:A prospective, open-label, non-randomized, phase II study was performed on 49 patients with locally advanced rectal cancer. Preoperative radiotherapy was c...

    journal_title:Cancer chemotherapy and pharmacology

    pub_type: 杂志文章,随机对照试验

    doi:10.1007/s00280-010-1469-8

    authors: Stojanovic S,Popov I,Radosevic-Jelic L,Micev M,Borojevic N,Nikolic V,Krivokapic Z,Kecmanovic D,Gavrilovic D,Kezic I

    更新日期:2011-09-01 00:00:00

  • A multi-institution phase II study of gemcitabine/cisplatin/S-1 (GCS) combination chemotherapy for patients with advanced biliary tract cancer (KHBO 1002).

    abstract:PURPOSE:Gemcitabine/cisplatin combination therapy has been the standard palliative chemotherapy for patients with advanced biliary tract cancer (BTC). We aimed to evaluate the efficacy and safety of adding S-1 to gemcitabine/cisplatin combination therapy for patients with advanced BTC. METHODS:Patients with histologic...

    journal_title:Cancer chemotherapy and pharmacology

    pub_type: 杂志文章,多中心研究

    doi:10.1007/s00280-014-2648-9

    authors: Kanai M,Hatano E,Kobayashi S,Fujiwara Y,Marubashi S,Miyamoto A,Shiomi H,Kubo S,Ikuta S,Yanagimoto H,Terajima H,Ikoma H,Sakai D,Kodama Y,Seo S,Morita S,Ajiki T,Nagano H,Ioka T

    更新日期:2015-02-01 00:00:00